Antidepressant use has increased steadily ([Stafford *et al*, 2001](#bib19){ref-type="other"}; [Pirraglia *et al*, 2003](#bib16){ref-type="other"}; [Meijer *et al*, 2004](#bib14){ref-type="other"}) since the introduction of selective serotonin reuptake inhibitors (SSRIs) in the late 1980s, with use reported by 10--20% of women in recent studies ([Moorman *et al*, 2003](#bib15){ref-type="other"}; [Steingart *et al*, 2003](#bib20){ref-type="other"}; [Chien *et al*, 2005](#bib4){ref-type="other"}), though actual use is likely to be higher due to underreporting ([Boudreau *et al*, 2004](#bib3){ref-type="other"}).

Antidepressants may affect the risk of breast cancer through the influence of prolactin, of which elevated levels have been observed with use of SSRIs, tricyclic antidepressants, and other psychotropic drugs ([Amsterdam *et al*, 1997](#bib1){ref-type="other"}; [Cowen and Sargent, 1997](#bib7){ref-type="other"}; [Emiliano and Fudge, 2004](#bib8){ref-type="other"}). Higher prolactin levels have been associated with an increased risk of postmenopausal breast cancer ([Hankinson *et al*, 1999](#bib10){ref-type="other"}; [Tworoger *et al*, 2004](#bib24){ref-type="other"}). However, the results of several studies of a possible association between antidepressant use and breast cancer risk have been inconsistent (see Discussion section).

To assess more completely the relation of breast cancer with antidepressant use, we conducted a large case control study using both computerized pharmacy records as well as records of reproductive history, family history of breast cancer, and other breast cancer risk factors. Breast cancer cases diagnosed during 1990--2001 were included, which allowed examination of newer SSRIs as well as tricyclic antidepressants.

METHODS
=======

All study subjects were enrollees of Group Health Cooperative (GHC), a health maintenance organization with over 500 000 members in western Washington State. Women with a new diagnosis of invasive or *in situ* breast cancer diagnosed between 1990 and 2001 were identified by routine linkage between the GHC enrollment file and the Seattle-Puget Sound [Surveillance, Epidemology, and End-Results SEER (2005)](#bib21){ref-type="other"}. Five controls were selected for each case matched on age, calendar year, and length of GHC membership, with the diagnosis date of the case assigned to each matched control as the reference date. To ensure more complete pharmacy records, we restricted cases and controls to women continuously enrolled at GHC for at least 4 years. We identified 2904 eligible cases age 30--79 when diagnosed with a first primary invasive or *in situ* breast cancer and 14396 eligible controls.

Since 1977, the GHC pharmacy database has included a record for all prescriptions dispensed to GHC enrollees. Each pharmacy record includes a patient identifier, the drug type and dose, date dispensed, quantity dispensed, and dosing instructions. Measures of antidepressant exposure included all prescriptions from the GHC enrollment start date up to 1 year prior to the reference date, with the exception of time since last use, which also included prescriptions filled in the year before the reference date. To provide some assurance that a prescribed drug was actually taken, we classified women as antidepressant users if they filled at least two prescriptions in a 6-month interval. We used number of prescriptions filled as a measure of duration of use, with a typical prescription filled for 1 month.

We examined antidepressant use overall, individual antidepressant medications, and four classes of antidepressants including SSRIs, tricyclics, monoamine oxidase inhibitors (MAOIs), and atypical antidepressants. The SSRI category included paroxetine, fluoxetine, sertraline, fluvoxamine, and citalopram. Tricyclic antidepressants included amitriptyline, doxepin, imipramine, desipramine, nortriptyline, protriptyline, amoxapine, trimipramine, and clomipramine. The MAOIs included phenelzine and tranylcypromine. Bupropion, mirtazapine, nefazodone, venlafaxine, maprotiline (a tetracyclic antidepressant), and trazodone were classified as 'atypical\' antidepressants.

Information on breast cancer risk factors and mammography history were obtained from the GHC Breast Cancer Screening Program (BCSP) databases ([Taplin *et al*, 1990](#bib22){ref-type="other"}). As part of the Breast Cancer Screening Program, self-administered questionnaires are first sent to all GHC women when they turn 40 (or enroll in GHC, whichever is later). Of eligible women, approximately 85--90% enroll in the BCSP and complete the initial questionnaire. The questionnaire includes information on clinical breast exams, previous mammograms, menopausal status, use of menopausal hormone replacement therapy, age at first birth, previous biopsies, family history of breast cancer, height, weight, education, and race. Selected questions from the BCSP questionnaire are updated at each screening visit. GHC also maintains databases of mammograms performed at GHC with dates of each mammogram, indications for examination (screening or diagnostic), type of evaluation (standard screening or diagnostic), results, and recommendations. Based on these records, we determined whether a study participant had had a screening mammogram in the 2 years prior to her diagnosis or reference date.

Unconditional logistic regression was used to compute odds ratios (as an estimate of relative risk) and 95% CI for duration and type of antidepressant use in relation to risk of breast cancer. All models included the matching factors (age at reference date, length of GHC membership, and reference year) as continuous variables. Family history of breast cancer, use and duration of HRT, body mass index, parity/age at first birth, and mammographic screening in the 2 years before reference date were determined to be potential confounders based on their associations with both exposure and disease. In addition to the matching factors, these factors were included in all multivariate models.

Our primary analyses included all women with invasive breast cancer and controls. Additional analyses examined ductal and lobular cases separately. We also conducted analyses separately of women with oestrogen receptor (ER) positive and ER negative tumours, based on routinely collected information from SEER. Polytomous regression models were used when cases were classified based on histology or ER status, which resulted in multiple case groups. To ensure more complete exposure data, some analyses were restricted to the subgroup of women enrolled in GHC for at least 10 years (over 70% of eligible subjects in this study). Cases with *in situ* disease were examined separately due to differences in the natural history ([Bodian, 1993](#bib2){ref-type="other"}; [Jensen and Page, 2003](#bib12){ref-type="other"}) and in some risk factors ([Weiss *et al*, 1996](#bib28){ref-type="other"}; [Trentham-Dietz *et al*, 2000](#bib23){ref-type="other"}; [Moorman *et al*, 2003](#bib15){ref-type="other"}) between invasive and *in situ* disease.

RESULTS
=======

Of the 2904 eligible cases, 2449 had invasive breast cancer and 455 had *in situ* carcinoma. Of the cases with invasive disease, 72% were ductal, 14% lobular or mixed lobular and ductal, and 14% were other histologies. Compared to controls, women with invasive breast cancer were more likely to report a family history of breast cancer, to be nulliparous, and to be at least 30 years old at first birth ([Table 1](#tbl1){ref-type="table"}). A higher percent of cases reported ever use of HRT and longer use of HRT. Women with invasive disease were slightly more likely to be overweight or obese than controls. The percentage of subjects with a screening mammogram within 2 years of the reference date was higher for invasive cases (71%) than for controls (58%) and cases were more likely to report a previous breast biopsy than controls.

Overall, 34% of women had filled at least 1 prescription for antidepressants up to 1 year before the diagnosis or reference date. About 24% had filled at least 2 antidepressant prescriptions within 6 months and were considered antidepressant users for this study. About 20% had filled at least 2 prescriptions for tricyclic antidepressants. For SSRIs, 6% had filled at least two prescriptions within 6 months and about 6% filled at least two prescriptions for atypical antidepressants. For each antidepressant class, women filled a median of 10 prescriptions.

Among controls, women who used antidepressants were more likely to report use of HRT than nonusers and had a longer duration of use than women who had not used antidepressants ([Table 2](#tbl2){ref-type="table"}). A higher percentage of women who used antidepressants were classified as obese than those who did not use antidepressants. Antidepressant users were also more likely to have had a screening mammogram within 2 years before the reference date and had been enrolled at GHC for a longer time than nonusers. Women who were older, had a younger age at menarche, a first birth before 20 years of age, or were white were more likely to use antidepressants, although these differences were relatively small.

When only adjusted for matching factors, the odds ratio for ever use of antidepressants was slightly elevated (OR=1.11 95% CI 1.00--1.22, *P*=0.048) ([Table 3](#tbl3){ref-type="table"}). After adjusting for potential confounding variables the OR was 1.04 (95% CI=0.94--1.16). Risk did not increase with increasing number of antidepressant prescriptions filled. The odds ratio for tricyclic use was slightly elevated when adjusted only for matching factors (OR=1.12, 95% CI 1.00--1.24), but not after additional adjustment (OR=1.06, 95% CI 0.94--1.19). The risk was not elevated with a greater number of tricyclic prescriptions filled. Ever use of SSRIs also was not associated with breast cancer risk (adjusted OR=0.98, 95% CI 0.80--1.18), nor was receipt of a relatively larger number of prescriptions. Use of atypical antidepressants was not associated with an increased risk of breast cancer.

In the analyses of the three most common tricyclic medications ([Table 4](#tbl4){ref-type="table"}), there was no association with doxepin or imipramine, but the odds ratios were somewhat elevated for amitriptyline. When accounting only for the matching factors, the odds ratio for ever use of amitriptyline was 1.27 (95% CI 1.10--1.47). The odds ratio was somewhat attenuated, but still slightly elevated (OR=1.21, 95% CI 1.03--1.41) after adjusting for potential confounding factors. No elevated risks were observed for the three most common SSRIs (fluoxetine, paroxetine, or sertraline) or with trazodone, the most common atypical antidepressant.

No patterns of increased risk were seen with time since first use or time since last use of tricyclics or SSRIs (data not shown).

In analyses by ER status, no associations were seen between antidepressant use overall, number of antidepressant prescriptions, SSRI use, number of SSRI prescriptions, tricyclic use, or number of tricyclic prescriptions with either ER+ or ER− breast cancer ([Table 5](#tbl5){ref-type="table"}). With the possible exception of amitriptyline, individual antidepressants were not associated with either ER+ or ER− breast cancer. In fully adjusted models for ER+ breast cancer, the OR for ever use of amitriptyline was 1.22 (95% CI 1.02--1.45). For 2--10 prescriptions of amitriptyline the OR was 1.19 (95% CI 0.95--1.48) and for 11 or more prescriptions the OR was 1.27 (95% CI 0.96--1.66). No associations were observed with other individual antidepressant medications (data not shown).

In the analysis of cases with invasive ductal carcinoma (data not shown), the odds ratios for the highest category of antidepressant use (OR=1.31, 95% CI 1.02--1.68) and the highest category of tricyclic use (OR=1.31, 95% CI 1.00--1.88) were somewhat elevated after adjusting for potential confounders. Risk was not elevated in any of the other categories of use, with no indication of a dose--response trend. No associations were seen between risk of ductal carcinoma and use of SSRIs or atypical antidepressants. Antidepressant use was not associated with invasive lobular carcinoma.

When analyses were restricted to women enrolled in GHC for at least 10 years, risks did not differ for antidepressants overall or any class of antidepressants (data not shown). Neither any use of antidepressants overall nor use of a particular class of antidepressants was associated with an increased risk of carcinoma *in situ* (data not shown).

DISCUSSION
==========

With few exceptions, no increased risks were observed between antidepressant use and risk of invasive breast cancer. After adjustment for potential confounding factors no associations were seen between risk of breast cancer and antidepressants overall, SSRIs, tricyclics, or atypical antidepressants. No increased risk was observed with time since first or last use of any class of antidepressants. When individual antidepressants were examined, only amitriptyline exhibited a possible, albeit weak, association (OR=1.21, 95% CI 1.03--1.41). Risks were not elevated for any other individual medications.

Similar to our study, most prior studies have found little or no association with ever use of antidepressants (all classes combined) ([Cotterchio *et al*, 2000](#bib6){ref-type="other"}; [Wang *et al*, 2001](#bib27){ref-type="other"}; [Moorman *et al*, 2003](#bib15){ref-type="other"}; [Steingart *et al*, 2003](#bib20){ref-type="other"}; [Chien *et al*, 2005](#bib4){ref-type="other"}), with increasing duration of use ([Cotterchio *et al*, 2000](#bib6){ref-type="other"}; [Wang *et al*, 2001](#bib27){ref-type="other"}; [Moorman *et al*, 2003](#bib15){ref-type="other"}; [Steingart *et al*, 2003](#bib20){ref-type="other"}; [Chien *et al*, 2005](#bib4){ref-type="other"}), or with time since first or last use ([Steingart *et al*, 2003](#bib20){ref-type="other"}; [Chien *et al*, 2005](#bib4){ref-type="other"}).

For use of tricyclic antidepressants, no increased risks were seen in most studies for current ([Chien *et al*, 2005](#bib4){ref-type="other"}; [Gonzalez-Perez and Garcia Rodriguez, 2005](#bib9){ref-type="other"}) or ever use ([Kelly *et al*, 1999](#bib13){ref-type="other"}; [Cotterchio *et al*, 2000](#bib6){ref-type="other"}; [Wang *et al*, 2001](#bib27){ref-type="other"}; [Sharpe *et al*, 2002](#bib18){ref-type="other"}; [Moorman *et al*, 2003](#bib15){ref-type="other"}; [Steingart *et al*, 2003](#bib20){ref-type="other"}; [Chien *et al*, 2005](#bib4){ref-type="other"}). In the present study, there was a weak positive association when adjusted only for matching factors and this was attenuated when adjusted for additional potential confounders. Longer duration of tricyclic use was associated with an increased risk of breast cancer (OR=2.1, 95% CI 0.9--5.0) in one study ([Cotterchio *et al*, 2000](#bib6){ref-type="other"}), but not in others ([Moorman *et al*, 2003](#bib15){ref-type="other"}; [Gonzalez-Perez and Garcia Rodriguez, 2005](#bib9){ref-type="other"}), including the present study, although cutpoints for the highest category of use have varied. Although we found a slightly increased risk with use of amitriptyline, other studies that examined individual tricyclic medications observed no increased risks associated with use of this drug ([Kelly *et al*, 1999](#bib13){ref-type="other"}; [Cotterchio *et al*, 2000](#bib6){ref-type="other"}; [Wang *et al*, 2001](#bib27){ref-type="other"}; [Steingart *et al*, 2003](#bib20){ref-type="other"}). [Sharpe *et al* (2002)](#bib18){ref-type="other"} reported an elevated risk of breast cancer associated with the tricyclic drugs classified as 'genotoxic\' based on *Drosophila* wing development ([van Schaik and Graf, 1991](#bib25){ref-type="other"}; [van Schaik and Graf, 1993](#bib26){ref-type="other"}). In the present study, no increased risk was observed either with an increasing number of prescriptions or timing of use of these same potentially genotoxic tricyclic medications (data not shown). In fact, in contrast to the findings by Sharpe *et al*, we found a slightly elevated risk of breast cancer associated with use of nongenotoxic tricyclic drugs, which includes the drug amitriptyline.

Most studies ([Kelly *et al*, 1999](#bib13){ref-type="other"}; [Cotterchio *et al*, 2000](#bib6){ref-type="other"}; [Wang *et al*, 2001](#bib27){ref-type="other"}; [Moorman *et al*, 2003](#bib15){ref-type="other"}; [Coogan *et al*, 2005](#bib5){ref-type="other"}; [Gonzalez-Perez and Garcia Rodriguez, 2005](#bib9){ref-type="other"}) have not found an association between ever use of SSRIs and risk of breast cancer, but one reported a slight increased risk (OR=1.32, 95% CI 0.97--1.80) ([Steingart *et al*, 2003](#bib20){ref-type="other"}). Although recent use of SSRIs was associated with an increased risk of breast cancer in one study ([Kelly *et al*, 1999](#bib13){ref-type="other"}), our study and others ([Chien *et al*, 2005](#bib4){ref-type="other"}; [Gonzalez-Perez and Garcia Rodriguez, 2005](#bib9){ref-type="other"}) that examined timing of use did not find a similar association. Duration of SSRI use has been assessed in this and other studies ([Kelly *et al*, 1999](#bib13){ref-type="other"}; [Cotterchio *et al*, 2000](#bib6){ref-type="other"}; [Moorman *et al*, 2003](#bib15){ref-type="other"}; [Chien *et al*, 2005](#bib4){ref-type="other"}; [Coogan *et al*, 2005](#bib5){ref-type="other"}; [Gonzalez-Perez and Garcia Rodriguez, 2005](#bib9){ref-type="other"}). One reported a doubling of the risk (OR=2.2, 95%CI=0.8--6.3) with duration of use longer than 3 years ([Moorman *et al*, 2003](#bib15){ref-type="other"}), but others have not observed an increased risk with increasing duration of use, although few women had used SSRIs for more than 2--3 years.

Individual SSRI medications have been associated with an increased risk of breast cancer in two previous studies ([Cotterchio *et al*, 2000](#bib6){ref-type="other"}; [Steingart *et al*, 2003](#bib20){ref-type="other"}), but not in others ([Chien *et al*, 2005](#bib4){ref-type="other"}; [Coogan *et al*, 2005](#bib5){ref-type="other"}; [Gonzalez-Perez and Garcia Rodriguez, 2005](#bib9){ref-type="other"}; [Haque *et al*, 2005](#bib11){ref-type="other"}) including our current study. Although one study reported an elevated odds ratio associated with use of sertraline (OR=1.45, 95% CI 0.88--2.40) ([Steingart *et al*, 2003](#bib20){ref-type="other"}), in our study and in others ([Cotterchio *et al*, 2000](#bib6){ref-type="other"}; [Coogan *et al*, 2005](#bib5){ref-type="other"}) the risk was not increased. The risk associated with paroxetine use has been substantially (OR=7.2, 95% CI 0.9--58.3) ([Cotterchio *et al*, 2000](#bib6){ref-type="other"}) and moderately (OR=1.45, 95% CI 0.88--2.40) ([Steingart *et al*, 2003](#bib20){ref-type="other"}) elevated in two studies, but not in ours or others ([Chien *et al*, 2005](#bib4){ref-type="other"}; [Coogan *et al*, 2005](#bib5){ref-type="other"}; [Gonzalez-Perez and Garcia Rodriguez, 2005](#bib9){ref-type="other"}; [Haque *et al*, 2005](#bib11){ref-type="other"}). We did not find an association with ever use of paroxetine (OR 1.00) or with increasing number of paroxetine prescriptions filled (OR 1.15 for 2--10 prescriptions and 0.52 for at least 11 prescriptions).

Atypical antidepressants have not shown an increased risk in this or other studies ([Moorman *et al*, 2003](#bib15){ref-type="other"}; [Chien *et al*, 2005](#bib4){ref-type="other"}). Trazodone was a commonly used antidepressant in our study population, but the number of women reporting use of atypical antidepressants has been quite low in other studies. Some studies relying on self-report may underestimate trazodone use if other indications of antidepressant use (such as insomnia) are not assessed.

The one other study that evaluated whether the risk associated with antidepressant use varies by ER status reported associations of antidepressant use with ER− tumors and with PR− tumors. The strongest association was observed with SSRIs in ER+/PR− cases (OR=2.0, 95% CI 1.1--3.8)([Chien *et al*, 2005](#bib4){ref-type="other"}). We did not find an association between SSRIs, tricyclics, or antidepressant use overall with either ER+ or ER− breast cancers. In contrast to the earlier study ([Chien *et al*, 2005](#bib4){ref-type="other"}), when we examined ER/PR combinations, risks were not elevated for ER+/PR− cases (data not shown).

Recently, one study reported that antidepressant users had a lower risk of breast cancer among women with a family history of breast cancer and a higher risk in those without a family history ([Chien *et al*, 2005](#bib4){ref-type="other"}). Our results do not replicate this interaction (data not shown).

Much of the prior research examining antidepressants and breast cancer risk has relied on the self-reported use of antidepressants ([Kelly *et al*, 1999](#bib13){ref-type="other"}; [Cotterchio *et al*, 2000](#bib6){ref-type="other"}; [Moorman *et al*, 2003](#bib15){ref-type="other"}; [Steingart *et al*, 2003](#bib20){ref-type="other"}; [Chien *et al*, 2005](#bib4){ref-type="other"}), but recall of prescription drugs varies according to the type of drug, the frequency of use, time since medication use, and education level ([Saunders *et al*, 1994](#bib17){ref-type="other"}; [West *et al*, 1995](#bib29){ref-type="other"}). Compared to pharmacy data, antidepressant use is substantially under-reported ([Boudreau *et al*, 2004](#bib3){ref-type="other"}). A study comparing self-reported use of antihypertensives, statins, and antidepressants with pharmacy data found higher agreement for antihypertensives and statins than for antidepressant medications. Antidepressant use was recalled only 62% of the time within 6 months prior to reference date, compared to 94% for antihypertensive use ([Boudreau *et al*, 2004](#bib3){ref-type="other"}). In addition, recall of names and dose of medication is relatively low ([West *et al*, 1995](#bib29){ref-type="other"}) and the percentage missing timing of use is relatively high ([Boudreau *et al*, 2004](#bib3){ref-type="other"}).

One strength of this study is the use of the GHC pharmacy records. Advantages of using administrative pharmacy records include having information available for all subjects (not only respondents), no under-reporting of use, no recall bias, and very complete information on drug name, dose, and timing of use. As most studies that use pharmacy databases to assess medication exposure have limited information on potential confounding factors ([Wang *et al*, 2001](#bib27){ref-type="other"}; [Sharpe *et al*, 2002](#bib18){ref-type="other"}; [Gonzalez-Perez and Garcia Rodriguez, 2005](#bib9){ref-type="other"}; [Haque *et al*, 2005](#bib11){ref-type="other"}), another important strength of the current study is the availability of breast cancer risk factor data.

One potential weakness of this study is the possibility that some women may have been prescribed antidepressants that were not included in the GHC pharmacy database. Prescriptions that were filled prior to the initiation of the pharmacy database in 1977, prior to enrollment in GHC, or filled out of the GHC system were not captured in the pharmacy databases. However, the number of antidepressants prescriptions filled outside the GHC system is likely to be small because antidepressant prescriptions were available free or with a small copayment for many GHC members. Further, others have reported that over 95% of prescriptions for antidepressants among GHC members are filled at a GHC pharmacy ([Saunders *et al*, 1994](#bib17){ref-type="other"}). While we could not identify antidepressant use prior to GHC membership, we conducted subset analyses among women with at least 10 years of pharmacy data to ensure more complete history of antidepressant use. Over 70% of the subjects in this study were enrolled for more than 10 years as of their reference date and the conclusions based on this restricted sample were unchanged.

Another potential limitation of this study is a relatively short follow-up time for paroxetine exposure. Paroxetine was on the market in the United States in 1993, but because it was not a preferred drug in the GHC formulary, it was not used often within GHC until 1997. As a result, fewer subjects in this study population had ever used paroxetine and the duration of use was shorter than what would be expected in the general population during the same time period.

Overall, the results from this and other epidemiologic studies do not provide evidence for an increased risk of breast cancer associated with the use of antidepressants overall, by class of drug, or for individual antidepressants. Although a few studies have reported elevated risks in select analyses, the findings have not been consistent by class of drug, type of individual drug, or timing of use. The lack of consistency across studies suggests that any observed elevated risks could be due to chance. If there were a causal relationship, breast cancer risk would likely increase with longer duration of exposure. A few studies have reported elevated risks in longer-term users of some agents ([Cotterchio *et al*, 2000](#bib6){ref-type="other"}; [Moorman *et al*, 2003](#bib15){ref-type="other"}), but the class has differed. Overall, risk of breast cancer has not varied in any systematic pattern by timing of antidepressant use. As SSRIs have only been available in the relatively recent past, we cannot rule out the possibility of an effect with longer duration or longer time since first use, but the accumulating evidence does not suggest an association.

We would like to thank Robert Harrison from Group Health Cooperative for his assistance with compiling data for this project. This research was funded by the National Cancer Institute (Grant No. RO3 CA 94745).

###### 

Characteristics of women with invasive breast cancer and controls

                                                                             **Cases (*N*=2449)**   **Controls (*N*=14396)**          
  ------------------------------------------------------------------------- ---------------------- -------------------------- ------- --------
  *Age at diagnosis/reference date*                                                                                                   
   30--39                                                                             92                      3.8               507     3.5
   40--49                                                                            461                      18.8             2878     20.0
   50--59                                                                            611                      25.0             3554     24.7
   60--69                                                                            618                      25.2             3646     25.3
   70+                                                                               667                      27.2             3811     26.5
                                                                                                                                          
  *Length of enrollment*                                                                                                              
   4--9                                                                              642                      26.2             3781     26.3
   10--19                                                                            1007                     41.1             5900     41.0
   20+ years                                                                         800                      32.7             4715     32.8
                                                                                                                                          
  *First degree family history of breast cancer*                                                                                      
   Yes                                                                               452                      20.6             1697     13.5
   No                                                                                1746                     79.4             10833    86.5
   Missing                                                                           251                     (10.3)            1866    (13.0)
                                                                                                                                          
  *Age at menarche*                                                                                                                   
   ⩽10                                                                               141                      6.0               740     5.6
   11--14                                                                            1936                     83.0             10879    82.5
   15+                                                                               256                      11.0             1566     11.9
   Missing                                                                           116                     (4.7)             1211    (8.4)
                                                                                                                                          
  *Parous*                                                                                                                            
   Yes                                                                               1910                     85.9             11037    87.6
   No                                                                                314                      14.1             1568     12.4
   Missing                                                                           225                     (9.2)             1791    (12.4)
                                                                                                                                          
  *Age at first birth (among parous women)*                                                                                           
   \<20                                                                              374                      19.6             2174     19.7
   20--24                                                                            816                      42.7             4804     43.5
   25--29                                                                            443                      23.2             2709     24.6
   30--34                                                                            218                      11.4              970     8.8
   35+                                                                                58                      3.0               377     3.4
   Missing                                                                            1                      (0.05)              4     (0.04)
                                                                                                                                          
  *Use of birth control pills*                                                                                                        
   Yes                                                                               1131                     53.8             6301     52.0
   No                                                                                973                      49.7             5821     48.0
   Missing                                                                           345                     (14.1)            2274    (15.8)
                                                                                                                                          
  *Ever use of HRT*                                                                                                                   
   Yes                                                                               1095                     50.3             5352     43.8
   No                                                                                1083                     49.7             6858     56.3
   Missing                                                                           271                     (11.1)            2186    (15.2)
                                                                                                                                          
  *Duration of use of HRT*                                                                                                            
   ⩾5 years                                                                          632                      29.0             2901     23.8
   \< 5 years                                                                        443                      20.3             2348     19.2
   Duration unknown                                                                   20                      0.9               103     0.8
   None                                                                              1083                     49.7             6858     56.2
   Missing                                                                           271                     (11.1)            2186    (15.2)
                                                                                                                                          
  *Body mass index*                                                                                                                   
   Normal (\<25)                                                                     1005                     46.0             6101     49.7
   Overweight (25--29.9)                                                             665                      30.4             3536     28.8
   Obese (30+)                                                                       516                      23.6             2631     21.5
   Missing                                                                           263                     (10.7)            2128    (14.8)
                                                                                                                                          
  *Race*                                                                                                                              
   White                                                                             1859                     90.8             9768     89.1
   Asian                                                                              87                      4.3               568     5.2
   Black                                                                              57                      2.8               351     3.2
   Multi/other                                                                        44                      2.2               275     2.5
   Missing                                                                           402                     (16.4)            3434    (23.9)
                                                                                                                                          
  *Education*                                                                                                                         
   Less than high school                                                             143                      6.7               792     7.2
   High school graduate                                                              499                      23.3             2627     23.8
   Some post secondary                                                               736                      34.3             3851     34.9
   College graduate                                                                  350                      16.3             1687     15.3
   Advanced degree/some graduate school                                              418                      19.5             2094     19.0
   Missing                                                                           303                     (12.4)            3345    (23.2)
                                                                                                                                          
  *Previous biopsy*                                                                                                                   
   Yes                                                                               574                      25.9             2156     17.2
   No                                                                                1640                     74.1             10406    82.8
   Missing                                                                           235                     (9.6)             1834    (12.7)
                                                                                                                                          
  *At least 1 screening mammogram within 2 years prior to reference date*                                                             
   Yes                                                                               1728                     70.6             8370     58.1
   No                                                                                721                      29.4             6026     41.9

###### 

Characteristics of antidepressant users and nonusers among controls

                                                                             **Antidepressant users (*N*=3426)**   **Nonusers (*N*=10970)**         
  ------------------------------------------------------------------------- ------------------------------------- -------------------------- ------ ------
  *Age at reference date*                                                                                                                           
   30--39                                                                                    70                              2.0              437    4.0
   40--49                                                                                    635                             18.5             2243   20.5
   50--59                                                                                    910                             26.6             2644   24.1
   60--69                                                                                    845                             24.7             2801   25.5
   70+                                                                                       966                             28.2             2845   25.9
                                                                                                                                                       
  *Length of enrollment*                                                                                                                            
   4--9                                                                                      745                             21.8             3036   27.7
   10--19                                                                                   1422                             41.5             4478   40.8
   20+ years                                                                                1259                             36.8             3456   31.5
                                                                                                                                                       
  *First degree family history of breast cancer*                                                                                                    
   Yes                                                                                       487                             15.6             1210   12.9
   No                                                                                       2638                             84.4             8195   87.1
                                                                                                                                                       
  *Age at menarche*                                                                                                                                 
   ⩽10                                                                                       218                             6.8              522    5.2
   11--14                                                                                   2653                             82.2             8226   82.6
   15+                                                                                       358                             11.1             1208   12.1
                                                                                                                                                       
  *Parous*                                                                                                                                          
   Yes                                                                                      2759                             87.6             8278   87.5
   No                                                                                        389                             12.4             1179   12.5
                                                                                                                                                       
  *Age at first birth*                                                                                                                              
   \<20                                                                                      684                             24.8             1490   18.0
   20--24                                                                                   1229                             44.6             3575   43.2
   25--29                                                                                    581                             21.0             2128   25.7
   30--34                                                                                    189                             6.9              781    9.4
   35+                                                                                       76                              2.8              301    3.6
                                                                                                                                                       
  *Ever use of HRT*                                                                                                                                 
   Yes                                                                                      1638                             53.8             3714   40.5
   No                                                                                       1405                             46.2             5453   59.5
                                                                                                                                                       
  *Duration of use of HRT*                                                                                                                          
   ⩾5 years                                                                                  923                             30.8             1978   21.7
   \<5 years                                                                                 673                             22.4             1675   18.4
   None                                                                                     1405                             46.8             5453   59.9
                                                                                                                                                       
  *Body mass index*                                                                                                                                 
   Normal (\<25)                                                                            1359                             44.2             4742   51.6
   Overweight (25--29.9)                                                                     855                             27.8             2681   29.2
   Obese (30+)                                                                               861                             28.0             1770   19.3
                                                                                                                                                       
  *Race*                                                                                                                                            
   White                                                                                    2502                             91.3             7266   88.4
   Asian                                                                                     74                              2.7              494    6.0
   Black                                                                                     84                              3.1              267    3.3
   Multi/other                                                                               81                              3.0              194    2.4
                                                                                                                                                       
  *Education*                                                                                                                                       
   Less than high school                                                                     221                             8.0              571    6.9
   High school graduate                                                                      683                             24.6             1944   23.5
   Some post secondary                                                                      1004                             36.1             2847   34.4
   College graduate                                                                          398                             14.3             1289   15.6
   Advanced degree/some graduate school                                                      473                             17.0             1621   19.6
                                                                                                                                                       
  *Previous biopsy*                                                                                                                                 
   Yes                                                                                       592                             18.9             1564   16.6
   No                                                                                       2547                             81.1             7859   83.4
                                                                                                                                                       
  *At least 1 screening mammogram within 2 years prior to reference date*                                                                           
   Yes                                                                                      2175                             63.5             6195   56.5
   No                                                                                       1251                             36.5             4775   43.5

###### 

Antidepressant use among women with invasive breast cancer and controls

                           **Cases (*N*=2449)**   **Controls (*N*=14396)**   **Adjusted for matching factors^a^ (*N*=16845)**   **Adjusted for potential confounding factors^b^ (*N*=13872)**         
  ----------------------- ---------------------- -------------------------- -------------------------------------------------- --------------------------------------------------------------- ------ ------------
  No antidepressants               1822                    10970                                   1.00                                                                                         1.00        
                                                                                                                                                                                                            
  *Antidepressants*                                                                                                                                                                                   
   Any use                         627                      3426                                   1.11                                                  1.00--1.22                             1.04   0.94--1.16
   2--10 prescriptions             276                      1503                                   1.11                                                  0.97--1.27                             1.04   0.90--1.21
   11--20 prescriptions            120                      627                                    1.16                                                  0.95--1.42                             1.10   0.89--1.38
   21--50 prescriptions            126                      760                                    1.01                                                  0.83--1.22                             0.94   0.76--1.16
   51+ prescriptions               105                      536                                    1.19                                                  0.96--1.48                             1.12   0.89--1.41
                                                                                                                                                                                                            
  *Tricyclics*                                                                                                                                                                                        
   Any use                         527                      2850                                   1.12                                                  1.00--1.24                             1.06   0.94--1.19
   2--10 prescriptions             273                      1484                                   1.11                                                  0.97--1.28                             1.05   0.90--1.22
   11--20 prescriptions             94                      490                                    1.16                                                  0.92--1.45                             1.13   0.89--1.44
   21--50 prescriptions             94                      557                                    1.02                                                  0.82--1.28                             0.96   0.76--1.23
   51+ prescriptions                66                      319                                    1.25                                                  0.96--1.64                             1.16   0.86--1.55
                                                                                                                                                                                                            
  *SSRIs*                                                                                                                                                                                             
   Any use                         154                      911                                    1.04                                                  0.86--1.24                             0.98   0.80--1.18
   2--10 prescriptions              78                      461                                    1.03                                                  0.81--1.32                             0.97   0.74--1.26
   11--20 prescriptions             35                      203                                    1.06                                                  0.73--1.52                             0.90   0.60--1.33
   21+ prescriptions                41                      247                                    1.02                                                  0.73--1.44                             1.04   0.73--1.48
                                                                                                                                                                                                            
  *Atypical*                                                                                                                                                                                          
   Any use                         150                      876                                    1.04                                                  0.87--1.25                             0.95   0.78--1.16
   2--10 prescriptions              90                      535                                    1.02                                                  0.81--1.29                             0.93   0.72--1.16
   11--20 prescriptions             23                      135                                    1.04                                                  0.99--1.92                             1.10   0.68--1.73
   21--50 prescriptions             24                      142                                    1.03                                                  0.66--1.59                             0.82   0.50--1.34
   51+ prescriptions                13                       64                                    1.25                                                  0.68--2.27                             1.13   0.60--2.13

Adjusted for age, length of enrollment, and calendar year.

Adjusted for age, length of enrollment, calendar year, family history of breast cancer, parity/age at first birth, duration of HRT use, body mass index, and history of screening mammogram in 2 years prior to reference date.

###### 

Use of specific antidepressant medications among women with invasive breast cancer and controls

                          **Cases**   **Controls**   **Adjusted for matching factors^a^**   **Adjusted for potential confounding factors^b^**         
  ---------------------- ----------- -------------- -------------------------------------- --------------------------------------------------- ------ ------------
  No antidepressants        1822         10970                       1.00                                                                       1.00        
                                                                                                                                                            
  *Tricyclics*                                                                                                                                        
  Amitriptyline                                                                                                                                             
   Any use                   250          1191                       1.27                                      1.10--1.47                       1.21   1.03--1.41
   2--10 prescriptions       151          756                        1.20                                      1.00--1.44                       1.17   0.97--1.43
   11+ prescriptions         99           435                        1.38                                      1.10--1.72                       1.26   0.99--1.60
                                                                                                                                                            
  Doxepin                                                                                                                                             
   Any use                   186          1101                       1.01                                      0.86--1.19                       0.95   0.79--1.13
   2--10 prescriptions       120          710                        1.01                                      0.83--1.23                       0.94   0.75--1.17
   11+ prescriptions         66           391                        1.01                                      0.78--1.32                       0.96   0.72--1.27
                                                                                                                                                            
  Imipramine                                                                                                                                                
   Any use                   127          683                        1.13                                      0.93--1.37                       1.04   0.84--1.29
   2--10 prescriptions       79           444                        1.08                                      0.84--1.38                       0.98   0.76--1.28
   11+ prescriptions         48           239                        1.22                                      0.89--1.67                       1.15   0.82--1.61
                                                                                                                                                            
  *SSRIs*                                                                                                                                             
  Fluoxetine                                                                                                                                                
   Any use                   114          611                        1.07                                      0.86--1.34                       1.00   0.80--1.25
   2--10 prescriptions       59           364                        0.99                                      0.75--1.31                       0.94   0.69--1.27
   11+ prescriptions         55           297                        1.14                                      0.85--1.53                       1.07   0.78--1.46
                                                                                                                                                            
  Paroxetine                                                                                                                                                
   Any use                   41           241                        1.05                                      0.75--1.48                       1.00   0.70--1.41
   2--10 prescriptions       36           178                        1.25                                      0.87--1.81                       1.15   0.79--1.69
   11+ prescriptions          5            63                        0.49                                      0.20--1.23                       0.52   0.21--1.31
                                                                                                                                                            
  Sertraline                                                                                                                                                
   Any use                   40           215                        1.15                                      0.82--1.62                       1.16   0.81--1.66
   2--10 prescriptions       24           129                        1.15                                      0.74--1.78                       1.18   0.75--1.86
   11+ prescriptions         16            86                        1.15                                      0.67--1.98                       1.12   0.64--1.98
                                                                                                                                                            
  *Atypical*                                                                                                                                                
  Trazodone                                                                                                                                                 
   Any use                   141          802                        1.07                                      0.89--1.29                       0.96   0.78--1.18
   2--10 prescriptions       82           502                        0.99                                      0.78--1.26                       0.88   0.68--1.15
   11+ prescriptions         59           300                        1.20                                      0.90--1.59                       1.09   0.80--1.49

Adjusted for age, length of enrollment, and calendar year.

Adjusted for age, length of enrollment, calendar year, family history of breast cancer, parity/age at first birth, duration of HRT use, body mass index, history of screening mammogram in 2 years prior to reference date.

###### 

Antidepressant use among women with invasive breast cancer, by ER status, and controls

                           **ER+ cases**   **ER-- cases**   **Controls**   **ER+ compared to controls^a^**   **ER− compared to controls^a^**         
  ----------------------- --------------- ---------------- -------------- --------------------------------- --------------------------------- ------ ------------
  No antidepressants           1307             325            10970                    1.00                                                   1.00        
                                                                                                                                                           
  *Antidepressant*                                                                                                                                   
   Any use                      457             106             3426                    1.05                           0.93--1.19              1.01   0.79--1.30
   2--10 prescriptions          207              45             1503                    1.09                           0.92--1.29              0.93   0.65--1.33
   11--20 prescriptions         95               16             627                     1.19                           0.94--1.51              0.87   0.50--1.50
   21--50 prescriptions         84               25             760                     0.85                           0.67--1.10              1.05   0.66--1.65
   51+ prescriptions            71               20             536                     1.04                           0.79--1.36              1.39   0.86--2.26
                                                                                                                                                           
  *Tricyclic*                                                                                                                                        
   Any use                      386              84             2850                    1.07                           0.94--1.21              0.95   0.72--1.24
   2--10 prescriptions          200              48             1484                    0.97                           0.68--1.38              1.06   0.90--1.26
   11--20 prescriptions         74               12             490                     0.92                           0.51--1.66              1.19   0.92--1.55
   21--50 prescriptions         67               10             557                     0.55                           0.27--1.13              0.94   0.72--1.25
   51+ prescriptions            45               14             319                     1.63                           0.91--2.90              1.09   0.77--1.60
                                                                                                                                                           
  *SSRI*                                                                                                                                             
   Any use                      108              28             911                     0.93                           0.74--1.16              1.05   0.69--1.60
   2--10 prescriptions          55               13             461                     0.92                           0.68--1.24              1.05   0.59--1.87
   11--20 prescriptions         26               7              203                     0.95                           0.61--1.47              0.87   0.35--2.15
   21+ prescriptions            27               8              247                     0.93                           0.62--1.41              1.21   0.58--2.51
                                                                                                                                                           
  *Atypical*                                                                                                                                         
   Any use                      108              31             876                     0.92                           0.73--1.16              1.15   0.76--1.74
   2--10 prescriptions          66               19             535                     0.93                           0.70--1.23              1.11   0.66--1.86
   11--20 prescriptions         17               6              135                     1.06                           0.62--1.80              1.76   0.76--4.07
   21+ prescriptions            25               6              206                     0.82                           0.52--1.31              0.89   0.36--2.20
                                                                                                                                                           
  *Amitriptyline*                                                                                                                                    
   Any use                      186              38             1191                    1.22                           1.02--1.45              1.09   0.75--1.58
   2--10 prescriptions          113              23             756                     1.19                           0.95--1.48              1.05   0.66--1.67
   11+ prescriptions            73               15             435                     1.27                           0.96--1.66              1.16   0.65--2.06

Adjusted for age, length of enrollment, calendar year, family history of breast cancer, parity/age at first birth, duration of HRT use, body mass index, and history of screening mammogram in 2 years prior to reference date.
